⚕ GetRetatrutide.ca

Retatrutide Reduces Obstructive Sleep Apnea Severity by 60% in Phase 3 TRIUMPH-1 Trial

Sleep Review reports that Eli Lilly's retatrutide reduced AHI by up to 36.1 events per hour (60.6%) in moderate-to-severe OSA, alongside average weight loss of 70.3 lbs over 80 weeks.

Eli Lilly’s investigational triple-agonist retatrutide has demonstrated clinically meaningful reductions in obstructive sleep apnea (OSA) severity in the Phase 3 TRIUMPH-1 trial, according to a detailed report from Sleep Review magazine published June 23, 2026.

The findings, presented at the American Diabetes Association’s 86th Scientific Sessions, add to the growing evidence that incretin-based therapies may benefit multiple obesity-related comorbidities — including a condition that affects approximately 3 million Canadians.

Key OSA Results

The TRIUMPH-1 trial included a nested basket focused on participants with moderate-to-severe OSA. At 80 weeks, retatrutide delivered:

  • A 60.6% reduction in AHI (apnea-hypopnea index): The primary measure of sleep apnea severity dropped by up to 36.1 events per hour from a baseline of 58.6 events per hour.
  • Substantial weight loss: Participants on the 12 mg dose lost an average of 70.3 lbs (28.3%) over 80 weeks, while those on the 9 mg dose lost 64.4 lbs (25.9%).
  • Obesity remission: 65.3% of participants on retatrutide 12 mg achieved a BMI below 30, no longer meeting the threshold for obesity.

“Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos,” said Dr. Ania Jastreboff, MD, PhD, professor of medicine and pediatrics at Yale School of Medicine and lead investigator of TRIUMPH-1. “In TRIUMPH-1 and TRANSCEND-T2D-1, treatment with retatrutide resulted in substantial weight reduction together with clinically meaningful improvements in glycemia, knee osteoarthritis pain, and obstructive sleep apnea.”

Kenneth Custer, PhD, executive vice president and president of Lilly Cardiometabolic Health, called the breadth of outcomes “striking to see with a single therapy,” noting that retatrutide delivered substantial weight loss, A1C reduction, and improvements in both knee osteoarthritis pain and moderate-to-severe OSA across the two Phase 3 programs.

Why This Matters for Sleep Medicine

Obstructive sleep apnea is a chronic condition in which the upper airway repeatedly collapses during sleep, causing intermittent hypoxia, fragmented sleep, and increased cardiovascular risk. Obesity is the single most important modifiable risk factor for OSA — excess adipose tissue in the neck and upper airway narrows the pharyngeal lumen, while central obesity impairs lung volume and respiratory mechanics.

Current standard treatment for moderate-to-severe OSA is continuous positive airway pressure (CPAP) therapy, which is effective but has adherence rates below 50% in many populations. CPAP addresses the mechanical obstruction but does not treat the underlying metabolic drivers. Weight loss has long been recognized as the most effective non-device intervention, with studies showing that a 10-15% reduction in body weight can reduce AHI by 25-50%.

If retatrutide’s 60.6% AHI reduction is replicated in dedicated OSA trials, it could represent a paradigm shift — a pharmacological intervention that treats both the root cause (obesity) and the downstream consequence (sleep apnea) simultaneously, potentially reducing or eliminating the need for CPAP in some patients.

Canadian Context

Obstructive sleep apnea is a significant health concern in Canada. According to the Public Health Agency of Canada, approximately 5.4 million Canadian adults (22%) have been diagnosed with sleep apnea or are at high risk, and the condition is substantially more common in individuals with obesity. OSA is associated with increased risks of hypertension, cardiovascular disease, stroke, and motor vehicle accidents due to daytime sleepiness.

Canadian-specific considerations include:

  • CPAP coverage varies by province: In Ontario, the Assistive Devices Program covers 75% of CPAP costs up to $1,081, but requires a sleep study and physician prescription. Other provinces have different coverage models, and many Canadians face out-of-pocket costs.
  • Weight-loss drug reimbursement gap: Neither semaglutide (Wegovy) nor tirzepatide (Zepbound) — the only approved GLP-1-based obesity treatments in Canada — are universally covered by provincial drug plans for obesity. Zepbound was recently approved by Health Canada for OSA in adults with obesity, but reimbursement remains limited.
  • Access to diagnostic sleep studies: Wait times for formal sleep studies in Canada can stretch months, particularly in smaller centres, creating barriers to OSA diagnosis and treatment.
  • Indigenous and remote communities: Sleep apnea prevalence may be higher in Indigenous populations due to higher rates of obesity and metabolic disease, yet access to both sleep diagnostics and weight-management interventions is limited in remote and northern communities.

A therapy that could simultaneously address obesity and sleep apnea would be particularly valuable in the Canadian healthcare context, where a single intervention could reduce the burden on two separate clinical pathways.

What Comes Next

Retatrutide is not yet approved by Health Canada, the FDA, or the EMA. The TRIUMPH-1 data will form part of Eli Lilly’s regulatory submission, which the company has indicated it plans to file in late 2026, with a potential commercial launch in 2027.

The TRIUMPH Phase 3 program includes four global registrational trials that have enrolled more than 5,800 participants. The TRANSCEND-T2D program for type 2 diabetes has enrolled more than 2,050 participants across three trials, with additional results expected over the next year.

Dedicated studies examining retatrutide’s effect on OSA as a primary endpoint — rather than as a nested analysis within an obesity trial — would strengthen the evidence base and inform clinical guidelines for the use of incretin therapies in sleep medicine.

Sources

← All news